Drugs / RLD2001-2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05191563 | Jul → Sep 2021 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07660796 Comparator | Jul 2026 → Oct 2027 expected | essential hypertension | Hanmi Pharmaceutical Company Limited | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04830449 Comparator | Oct 2020 → Aug 2021 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLD2001-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04830449 ↗ |
| Route | Oral | “Take it once daily for 8 weeks orally.” NCT04830449 ↗ |